Alcon bought Aerie Pharmaceuticals Aerie Pharmaceuticals from 11/22/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Alcon completed its acquisition of Aerie Pharmaceuticals for $770 million, or 15.25 per share.

Aerie Pharmaceuticals

Review

Source:

{source} pictogram

investor.alcon.com

Vladimir Petenev

News editor

Write your comment first

News feed

Rosseti South reported for 6 months of 2024 by IFRS

8/27/24 MRKY

Magnit.Market increased the network of PVZ up to 2000 points

8/27/24 MGNT

Rosseti Kuban reported for 6 months of 2024 by IFRS

8/27/24 KUBE

Rosseti Volga reported for 6 months of 2024 by IFRS

8/27/24 MRKV

Polyus increased gold production by 3%

8/27/24 PLZL

Polyus reported for 6 months of 2024 by IFRS

8/27/24 PLZL

Dorogobuzh reported 6 months of 2024 by IFRS

8/27/24 DGBZ

Akron's sales grew by 2% in the first half of the year

8/27/24 AKRN

Rosseti Urals reported for 6 months of 2024 by IFRS

8/27/24 MRKU

Acron reports for 6 months of 2024 by IFRS

8/27/24 AKRN